早期代谢标志物可识别2型糖尿病预防的潜在靶点
研究在芬兰Botnia前瞻性队列543名非糖尿病个体(10年随访146人进展为2型糖尿病)中,用靶向及非靶向代谢组学检测568种代谢物,通过机器学习筛选预测标志物,并在法国DESIR队列1044人(9年随访231人进展)中重复验证。基于全部代谢组的模型预测进展的AUC=0.77,显著优于仅用临床危险因素的参考模型(AUC=0.68;DeLong p=0.0009);机器学习筛选的标志物组合AUC=0.78(p=0.00019;IDI=66.7%)。研究识别出α-生育酚、缓激肽羟脯氨酸、X-12063和X-13435等新预测生物标志物,与葡萄糖、甘露糖、α-羟基丁酸及常规临床危险因素联合时显示附加预测价值。作者认为该研究为未来2型糖尿病预防工作提供了一组新代谢标志物。
要点
- 在芬兰Botnia前瞻性队列543名非糖尿病个体中,基于全部代谢组的机器学习模型预测2型糖尿病进展的AUC=0.77,优于仅用临床危险因素的参考模型AUC=0.68(DeLong p=0.0009)。
- 机器学习筛选的代谢标志物组合预测进展的AUC=0.78(p=0.00019;IDI=66.7%),并在法国DESIR队列1044人中重复验证。
- α-生育酚、缓激肽羟脯氨酸、X-12063和X-13435等新标志物与葡萄糖、甘露糖、α-羟基丁酸及常规临床危险因素联合时显示附加预测价值。
核心结论
- 本研究提供了一组用于未来2型糖尿病预防工作的新代谢标志物。
研究设计与样本
- 在芬兰Botnia前瞻性研究543名非糖尿病个体(10年随访期间146人进展为2型糖尿病)中,采用质谱靶向及全局非靶向代谢组学检测568种代谢物。
- 使用多变量逻辑回归评估统计关联,采用正则化最小二乘建模进行机器学习风险分类和标志物筛选,并通过重复嵌套交叉验证评估预测性能。
- 在法国DESIR研究独立队列1044人(9年随访期间231人进展为2型糖尿病)中重复验证。
主要发现
- 9种代谢物与2型糖尿病进展呈负相关(可能具有保护作用),25种呈正相关。
- 基于全部代谢组的机器学习模型预测2型糖尿病进展的AUC=0.77,显著优于仅基于临床危险因素的参考模型AUC=0.68(DeLong p=0.0009)。
- 机器学习特征筛选出的代谢标志物组合预测性能亦显著优于参考模型(AUC=0.78;p=0.00019;IDI=66.7%)。
- 识别出α-生育酚、缓激肽羟脯氨酸、X-12063和X-13435等新预测生物标志物,与葡萄糖、甘露糖、α-羟基丁酸及常规临床危险因素联合时显示附加预测价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aims of this study were to evaluate systematically the predictive power of comprehensive metabolomics profiles in predicting the future risk of type 2 diabetes, and to identify a panel of the most predictive metabolic markers. METHODS: We applied an unbiased systems medicine approach to mine metabolite combinations that provide added value in predicting the future incidence of type 2 diabetes beyond known risk factors. We performed mass spectrometry-based targeted, as well as global untargeted, metabolomics, measuring a total of 568 metabolites, in a Finnish cohort of 543 non-diabetic individuals from the Botnia Prospective Study, which included 146 individuals who progressed to type 2 diabetes by the end of a 10 year follow-up period. Multivariate logistic regression was used to assess statistical associations, and regularised least-squares modelling was used to perform machine learning-based risk classification and marker selection. The predictive performance of the machine learning models and marker panels was evaluated using repeated nested cross-validation, and replicated in an independent French cohort of 1044 individuals including 231 participants who progressed to type 2 diabetes during a 9 year follow-up period in the DESIR (Data from an Epidemiological Study on the Insulin Resistance Syndrome) study. RESULTS: Nine metabolites were negatively associated (potentially protective) and 25 were positively associated with progression to type 2 diabetes. Machine learning models based on the entire metabolome predicted progression to type 2 diabetes (area under the receiver operating characteristic curve, AUC = 0.77) significantly better than the reference model based on clinical risk factors alone (AUC = 0.68; DeLong's p = 0.0009). The panel of metabolic markers selected by the machine learning-based feature selection also significantly improved the predictive performance over the reference model (AUC = 0.78; p = 0.00019; integrated discrimination improvement, IDI = 66.7%). This approach identified novel predictive biomarkers, such as α-tocopherol, bradykinin hydroxyproline, X-12063 and X-13435, which showed added value in predicting progression to type 2 diabetes when combined with known biomarkers such as glucose, mannose and α-hydroxybutyrate and routinely used clinical risk factors. CONCLUSIONS/INTERPRETATION: This study provides a panel of novel metabolic markers for future efforts aimed at the prevention of type 2 diabetes.
引用
- Peddinti G, Cobb J, Yengo L, et al. Early metabolic markers identify potential targets for the prevention of type 2 diabetes. Diabetologia. 2017. PMID: 28597074. doi:10.1007/s00125-017-4325-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。